vTv Therapeutics (NASDAQ:VTVT) Now Covered by StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a report issued on Thursday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Alliance Global Partners started coverage on shares of vTv Therapeutics in a report on Monday, December 9th. They issued a “buy” rating and a $35.00 price objective for the company.

vTv Therapeutics Stock Up 0.1 %

Shares of NASDAQ VTVT opened at $17.21 on Thursday. vTv Therapeutics has a 52-week low of $12.12 and a 52-week high of $29.19. The business’s 50 day moving average is $17.19 and its two-hundred day moving average is $15.49. The firm has a market cap of $54.90 million, a price-to-earnings ratio of -3.80 and a beta of 1.07.

vTv Therapeutics (NASDAQ:VTVT) last posted its earnings results on Thursday, March 20th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.32. The firm had revenue of $0.02 million for the quarter.

Institutional Investors Weigh In On vTv Therapeutics

Several large investors have recently bought and sold shares of VTVT. Geode Capital Management LLC grew its position in shares of vTv Therapeutics by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock worth $158,000 after buying an additional 1,327 shares in the last quarter. JPMorgan Chase & Co. purchased a new position in vTv Therapeutics in the fourth quarter worth approximately $25,000. Finally, FMR LLC acquired a new position in vTv Therapeutics during the 3rd quarter worth approximately $2,402,000. Hedge funds and other institutional investors own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.